NICE technology appraisal guidance
Issued: July 2010
TA193
Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia
This is an extract from the guidance and may be misleading if read alone. The complete guidance is available at guidance.nice.org.uk/ta193
Important information about this guidance
This guidance was developed using the NICE single technology appraisals process: www.nice.org.uk/aboutnice/howwework/devnicetech/developing_nice_technology_appraisals.jsp